Search Results - "Berquist, Lisa"

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity by Dong, Jianying, Sereno, Arlene, Snyder, William B., Miller, Brian R., Tamraz, Susan, Doern, Adam, Favis, Michael, Wu, Xiufeng, Tran, Hon, Langley, Emma, Joseph, Ingrid, Boccia, Antonio, Kelly, Rebecca, Wortham, Kathleen, Wang, Qin, Berquist, Lisa, Huang, Flora, Gao, Sharon X., Zhang, Ying, Lugovskoy, Alexey, Martin, Shelly, Gouvis, Heather, Berkowitz, Steven, Chiang, Gisela, Reff, Mitchell, Glaser, Scott M., Hariharan, Kandasamy, Demarest, Stephen J.

“…Bispecific antibodies (BsAbs) target multiple epitopes on the same molecular target or different targets. Although interest in BsAbs has persisted for decades,…”
Get full text

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity by Dong, Jianying, Sereno, Arlene, Aivazian, Dikran, Langley, Emma, Miller, Brian R., Snyder, William B, Chan, Eric, Cantele, Matt, Morena, Ronald, Joseph, Ingrid B.J.K., Boccia, Antonio, Virata, Cyrus, Gamez, James, Yco, Grace, Favis, Michael, Wu, Xiufeng, Graff, Christilyn P., Wang, Qin, Rohde, Ellen, Rennard, Rachel, Berquist, Lisa, Huang, Flora, Zhang, Ying, Gao, Sharon X., Ho, Steffan N., Demarest, Stephen J., Reff, Mitchell E., Hariharan, Kandasamy, Glaser, Scott M.

“…The epidermal growth factor receptor (EGFR) and the type I insulin-like growth factor receptor (IGF-1R) are two cell surface receptor tyrosine kinases known to…”
Get full text

Development of an Fn14 agonistic antibody as an anti-tumor agent by Michaelson, Jennifer S., Amatucci, Aldo, Kelly, Rebecca, Su, Lihe, Garber, Ellen, Day, Eric S., Berquist, Lisa, Cho, Sandy, Li, You, Parr, Michael, Wille, Laure, Schneider, Pascal, Wortham, Kathleen, Burkly, Linda C., Hsu, Yen-Ming, Joseph, Ingrid B.J.K.

“…TWEAK, a TNF family ligand with pleiotropic cellular functions, was originally described as capable of inducing tumor cell death in vitro. TWEAK functions by…”
Get full text

Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties by Doern, Adam, Cao, Xianjun, Sereno, Arlene, Reyes, Christopher L., Altshuler, Angelina, Huang, Flora, Hession, Cathy, Flavier, Albert, Favis, Michael, Tran, Hon, Ailor, Eric, Levesque, Melissa, Murphy, Tracey, Berquist, Lisa, Tamraz, Susan, Snipas, Tracey, Garber, Ellen, Shestowsky, William S., Rennard, Rachel, Graff, Christilyn P., Wu, Xiufeng, Snyder, William, Cole, Lindsay, Gregson, David, Shields, Michael, Ho, Steffan N., Reff, Mitchell E., Glaser, Scott M., Dong, Jianying, Demarest, Stephen J., Hariharan, Kandasamy

“…Therapeutic antibodies directed against the type 1 insulin-like growth factor receptor (IGF-1R) have recently gained significant momentum in the clinic because…”
Get full text

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine by HARIHARAN, KANDASAMY, CHU, PETER, MURPHY, TRACEY, CLANTON, DANA, BERQUIST, LISA, MOLINA, ARTURO, HO, STEFFAN N, VEGA, MARIO I, BONAVIDA, BENJAMIN

“…Galiximab is a primatized monoclonal antibody that targets CD80 expressed on malignant B cells and is being studied in the clinic as a potential treatment for…”
Get full text

Inhibition of B-NHL Tumor Xenografts Following Treatment with Galiximab (Anti-CD80 mAb) and Potentiation When Combined with Chemotherapy by Vega, Mario I, Hariharan, Hari, Chu, Peter, Murphy, Tracey, Clanton, Dana, Berquist, Lisa, Molina, Arturo, Ho, Steffan, Bonavida, Benjamin

“…Abstract 4873 The non-Hodgkin's lymphomas (NHLs) are a group of lymphoproliferative malignancies with divergent clinical courses. Although the NHLs have…”
Get full text

Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties: IMPLICATIONS FOR MECHANISM OF ACTION IN VIVO by Doern, Adam, Cao, Xianjun, Sereno, Arlene, Reyes, Christopher L, Altshuler, Angelina, Huang, Flora, Hession, Cathy, Flavier, Albert, Favis, Michael, Tran, Hon, Ailor, Eric, Levesque, Melissa, Murphy, Tracey, Berquist, Lisa, Tamraz, Susan, Snipas, Tracey, Garber, Ellen, Shestowsky, William S, Rennard, Rachel, Graff, Christilyn P, Wu, Xiufeng, Snyder, William, Cole, Lindsay, Gregson, David, Shields, Michael, Ho, Steffan N, Reff, Mitchell E, Glaser, Scott M, Dong, Jianying, Demarest, Stephen J, Hariharan, Kandasamy

“…Therapeutic antibodies directed against the type 1 insulin-like growth factor receptor (IGF-1R) have recently gained significant momentum in the clinic because…”
Get full text

Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX by Hariharan, K, Braslawsky, G, Barnett, R S, Berquist, L G, Huynh, T, Hanna, N, Black, A

“…Induction of CD8+ cytotoxic T lymphocytes (CTLs) specific for human papillomavirus (HPV) antigens provides an attractive strategy for immunotherapy of…”
Get more information